1. Introduction {#sec1-cancers-09-00163}
===============

As the second most common cause of cancer-related death \[[@B1-cancers-09-00163]\], colorectal cancer (CRC) represents a major worldwide health burden. CRC is the third most commonly diagnosed cancer in men and the second in women, with the highest prevalence in Australasia, the Asia-Pacific, Western Europe, and North America \[[@B1-cancers-09-00163]\]. In the United States in 2016, there were approximately 134,490 new cases of CRC (representing 8% of all new cancer cases), and 49,190 estimated deaths \[[@B2-cancers-09-00163]\].

Surgical resection combined with chemotherapy (with or without radiotherapy) is the standard CRC treatment \[[@B3-cancers-09-00163],[@B4-cancers-09-00163],[@B5-cancers-09-00163]\]. Due to local anatomy, surgery alone is usually insufficient to manage patients with rectal cancer; limited operative access, the distance between the tumor border and the mesorectal fascia, and vicinity to the pelvic organs all contribute to recurrence \[[@B6-cancers-09-00163]\]. Additionally, rectal cancer patients consistently have poorer survival outcomes than those with colon cancer \[[@B7-cancers-09-00163]\]. When compared to surgery alone, the use of preoperative (neoadjuvant) radiotherapy significantly reduces the risk of recurrence and improves overall survival (OS) and cancer-specific survival \[[@B8-cancers-09-00163],[@B9-cancers-09-00163],[@B10-cancers-09-00163]\].

The DNA damage response (DDR) signaling pathways identify and repair DNA damage \[[@B11-cancers-09-00163]\]. Cells with defective DDR are unable to repair radiation-induced DNA double-strand breaks and therefore have increased sensitivity to radiotherapy. Hence, molecules that are involved in DDR are excellent candidates for radiosensitivity biomarkers \[[@B11-cancers-09-00163]\]. Importantly, abnormalities in DDR mechanisms are linked to carcinogenesis in many human cancers, including CRC. In particular, mismatch repair (MMR) proteins recognize and repair single-nucleotide mismatches in microsatellite sequences that have escaped DNA polymerase proofreading \[[@B12-cancers-09-00163]\]. Approximately 15% of CRCs have mutations in MMR proteins, causing error accumulation during DNA replication and recombination, which result in microsatellite instability (MSI) \[[@B12-cancers-09-00163]\]. The MSI tumor phenotype is of potential clinical significance as a predictor of therapeutic efficacy and prognosis; for example, compared with microsatellite-stable (MSS) tumors with a functional MMR system, MSI tumors have better prognosis \[[@B13-cancers-09-00163]\] but exhibit variable treatment outcomes in response to DNA-targeting chemotherapeutic agents \[[@B14-cancers-09-00163]\].

The MRN complex comprising of DNA repair proteins MRE11, RAD50 and NBS1 (MRE11/RAD50/NBS1) detects and repairs double-strand breaks, and is therefore critical for maintaining genomic integrity and suppressing tumor progression \[[@B15-cancers-09-00163],[@B16-cancers-09-00163],[@B17-cancers-09-00163]\]. Several studies have shown that MRE11 and/or RAD50 mutations often occur in MSI CRC \[[@B14-cancers-09-00163],[@B18-cancers-09-00163]\]. Furthermore, RAD50 is more commonly overexpressed in MSS tumors, while it is more often mutated in MSI tumors \[[@B19-cancers-09-00163]\]. Similarly, MRE11 is a valuable prognostic marker in CRC \[[@B20-cancers-09-00163]\], and its deficiency is associated with improved OS and disease-free survival (DFS) in patients with stage III colon cancer, irrespective of treatment \[[@B21-cancers-09-00163]\].

Together with the radiosensitivity index \[[@B11-cancers-09-00163],[@B22-cancers-09-00163]\], MRE11 has been the most studied MRN complex component, and its prognostic value has been assessed in different cancers \[[@B15-cancers-09-00163],[@B23-cancers-09-00163]\], including CRC \[[@B18-cancers-09-00163],[@B20-cancers-09-00163],[@B24-cancers-09-00163],[@B25-cancers-09-00163]\]. However, to date, there is no data available on RAD50 as a specific biomarker in rectal cancer. A recent study evaluated all three MRN proteins together with clinicopathological factors in low-grade epithelial ovarian cancer, and found that RAD50 loss occurred in 10% of cases and was associated with MMR deficiency \[[@B26-cancers-09-00163]\]. Based on the key role played by RAD50 in DNA damage repair \[[@B11-cancers-09-00163]\], we hypothesized that different expression levels of this protein might impact upon treatment outcomes.

In this study, we evaluated the role of RAD50 as a potential prognostic marker in patients with incident cases of rectal cancer treated with surgery and radiotherapy. We correlated postoperative RAD50 tumor expression with patient DFS and OS. Additionally, we assessed the influence of RAD50 expression on other relevant tumor clinico-histopathological variables such as perineural invasion.

2. Results {#sec2-cancers-09-00163}
==========

2.1. Study Population {#sec2dot1-cancers-09-00163}
---------------------

A total of 266 patients were included in this study; 176 (66.2%) were male, 90 (33.8%) were female, and the median age was 72 years (range: 35--100 years) ([Table 1](#cancers-09-00163-t001){ref-type="table"}). Of 266 patients, 77 (31.3%) were treated with radiotherapy, 55 of which (71.4%) received preoperative therapy. Patients were followed for a median period of 3.16 years (range: 0−12.6 years), and the median time to death was 2.5 years after surgery (range: 0−11.1 years).

2.2. Association between RAD50 Expression and Clinicopathological Features and Prognosis {#sec2dot2-cancers-09-00163}
----------------------------------------------------------------------------------------

The association between postoperative RAD50 expression and clinicopathological characteristics is presented in [Table 2](#cancers-09-00163-t002){ref-type="table"}. Low RAD50 expression levels in the tumor periphery (TP) were significantly associated with adjuvant therapy treatment (*p* = 0.04). There were no significant differences in age, sex, histological tumor stage, lymph node involvement, metastasis, vascular invasion, or perineural invasion between patients with low and high RAD50 expression. Kaplan--Meier survival analysis demonstrated that low RAD50 expression in the tumor center (TC) was significantly associated with worse DFS (*p* = 0.016; [Figure 1](#cancers-09-00163-f001){ref-type="fig"}A), whereas the association of RAD50 expression and OS was of borderline significance (*p* = 0.056; [Figure 1](#cancers-09-00163-f001){ref-type="fig"}B). No significant difference in survival was seen between patients with high or low RAD50 expression in the TP (DFS, *p* = 0.295; OS, *p* = 0.695) ([Figure 1](#cancers-09-00163-f001){ref-type="fig"}C,D).

To explore the association between RAD50 scores and clinical prognosis, the samples were further categorized into a high expression group (score range: 6--12), a medium-low expression group (score range: 4--\<6), and a very low expression group (score range: 0--\<4). Kaplan--Meier survival analysis revealed that very low RAD50 expression in the TC was significantly associated with worse DFS (*p* = 0.031) and decreased OS (*p* = 0.044), indicating that the loss of RAD50 expression would possibly increase tumor aggressiveness ([Figure S1A,B](#app1-cancers-09-00163){ref-type="app"}). No significant change was found between patients with high, medium-low, or/and very low RAD50 expression in the TP (DFS, *p* = 0.111; OS, *p* = 0.638; [Figure S1C,D](#app1-cancers-09-00163){ref-type="app"}).

We next investigated the status of the MMR pathway in patient samples by evaluating the association of MMR proteins with RAD50 expression. All cases were positive for MLH1 (MutL protein homolog 1) and MSH2 (MutS protein homolog 2) expression; therefore, none of the cases were classified as MSI-high (MMR-negative). Expression of MSH6 (MutS protein homolog 6) and PMS2 (PMS1 homolog 2) were negative in 2/253 (0.8%) and 9/253 (3.6%) cases, respectively. Additionally, no significant associations of RAD50 and MSH6 expression in either TC or TP samples were found. Finally, low postoperative RAD50 expression was significantly associated with PMS2 expression in the TC (*p* = 0.04), but not in the TP (*p* = 0.36) ([Table 2](#cancers-09-00163-t002){ref-type="table"}).

We found that low expression of RAD50 in the TC (HR (hazard ratio) = 0.552, 95% CI 0.339--0.899, *p* = 0.017; univariate Cox regression) was significantly associated with reduced DFS ([Table 3](#cancers-09-00163-t003){ref-type="table"}). Representative immunohistochemical staining of high and low RAD50 expression in rectal cancer tissues are shown in [Figure 2](#cancers-09-00163-f002){ref-type="fig"}A,B. Additionally, using multivariate Cox analysis, we found that RAD50 expression (HR = 0.567, 95% CI 0.345--0.931, *p* = 0.025) and perineural invasion (HR = 2.364, 95% CI 1.343--4.162, *p* = 0.003) remained significantly associated with DFS ([Table 3](#cancers-09-00163-t003){ref-type="table"}). However, in multivariate Cox analysis with OS, perineural invasion (HR = 1.701, 95% CI 1.036--2.792, *p* = 0.036) remained significantly associated with OS, but not with tumor RAD50 expression (HR = 0.712, 95% CI 0.462--1.095, *p* = 0.122) ([Table S1](#app1-cancers-09-00163){ref-type="app"}). Finally, using Kaplan--Meier analysis of DFS to compare RAD50 low and high expression groups with tumors classified by perineural invasion status, we found that low levels of RAD50 expression in rectal cancer tissues were significantly associated with perineural invasion ([Figure 2](#cancers-09-00163-f002){ref-type="fig"}C,D), indicating that low RAD50 in the context of PNI (perineural invasion) is a marker of poor prognosis.

2.3. RAD50 Expression as a Putative Prognostic Factor for Early Stage Rectal Cancer {#sec2dot3-cancers-09-00163}
-----------------------------------------------------------------------------------

The DFS of rectal cancer patients with low RAD50 expression was worse than the DFS of patients with high RAD50 expression. When patients were grouped into early tumor stage (T1--2) and low-grade (G1--2) subgroups, low expression of RAD50 was associated with decreased DFS (*p* = 0.001) ([Figure 2](#cancers-09-00163-f002){ref-type="fig"}E), indicating that RAD50 may be a useful prognostic biomarker for early tumor stage and low-grade subgroups. Similarly, low RAD50 expression in early tumor stage and low-grade tumor subgroups was significantly associated with worse OS (*p* \< 0.001) ([Figure 2](#cancers-09-00163-f002){ref-type="fig"}F). Additional Cox regression analyses confirmed that expression of RAD50 in early tumor stage and low-grade subgroups significantly correlated with DFS (HR = 0.218, 95% CI 0.084--0.570, *p* = 0.002) ([Table 3](#cancers-09-00163-t003){ref-type="table"}).

3. Discussion {#sec3-cancers-09-00163}
=============

Colon and rectal cancers are often considered as a single entity and are treated with similar approaches. However, rectal cancers, particularly localized rectal cancers, may benefit from a different approach. In this study, we evaluated RAD50 expression by immunohistochemistry in 266 rectal cancer samples, taking into account several clinicopathological characteristics, as well as the type of treatment received. We discovered that low levels of RAD50 expression at early tumor stages and low-grade tumor subgroups were significantly associated with worse DFS and OS, indicating a relationship between postoperative tumor expression of RAD50 and prognosis.

Long-term clinical trials \[[@B27-cancers-09-00163],[@B28-cancers-09-00163]\] and several meta-analyses \[[@B8-cancers-09-00163],[@B10-cancers-09-00163],[@B29-cancers-09-00163]\] have confirmed that neoadjuvant radiotherapy plus surgery reduces the rate of local recurrence and increases the survival rate of rectal cancer patients, benefits that outweigh the associated side effects. Patients with rectal cancer can have variable responses to radiotherapy; therefore, the identification of rectal cancer-specific radiosensitivity and prognostic markers would enable targeted therapeutic decisions, which would likely improve treatment results and survival rates. For example, it would be useful to identify biomarkers that discriminate between patients who are likely to benefit from neoadjuvant (preoperative) radiotherapy and those who would respond better to adjuvant (postoperative) radiotherapy.

Based on this premise, we investigated RAD50 as a prognostic biomarker in rectal cancer. Together with MRE11 and NBS1, RAD50 is part of the MRN complex, which is heavily involved in maintenance of genomic integrity and tumor suppression \[[@B15-cancers-09-00163]\]. An intact MRN complex predicts a good response to treatment in patients with early breast cancer \[[@B30-cancers-09-00163]\], whereas mutations in MRE11, NBS1, or RAD50 have been linked to increased risk of cancer, including sporadic and familial cancers \[[@B17-cancers-09-00163]\].

We correlated the clinicopathological characteristics and treatment type with long-term (DFS and OS) radiotherapy responses. Specifically, the results from univariate and multivariate analyses showed that worse DFS outcomes were associated not only with low RAD50 expression in the TC, but also with perineural invasion. These data indicate that postoperative RAD50 expression predicts long-term survival if evaluated with other tumor-related clinicopathological features.

We found that low postoperative RAD50 expression was associated with reduced DFS and OS in early tumor stage (T1--2) and low-grade (G1--2) patient subgroups, supporting the potential use of RAD50 as an early prognostic biomarker in rectal cancer. The role of RAD50 has also been evaluated in CRC. Of interest, Gao et al. \[[@B19-cancers-09-00163]\] demonstrated that RAD50 expression is weak in MSI CRCs and is not associated with clinicopathological characteristics. Conversely, they observed increased RAD50 expression in early stage primary MSS CRCs. Interestingly, they found that the oncogenic RAD50 frameshift mutation (A)^9^ occurred in MSI, but not in MSS CRCs, which suggests that RAD50 might play different roles in these CRC phenotypic subtypes \[[@B19-cancers-09-00163]\].

Importantly, RAD50 was identified as a prognostic biomarker for colorectal mucinous adenocarcinoma (10--15% of all cases) through an integrated analysis of genetic and epigenetic features \[[@B31-cancers-09-00163]\]. The authors of this study showed that weak RAD50 expression was associated with poor prognosis in patients with MSS CRC, and postulated that increased RAD50 expression in MSS CRC could be a tumor suppressive cellular response to prevent further tumor progression \[[@B31-cancers-09-00163]\]. Based on these reports, further investigation of the molecular role of RAD50 in MSI and MSS CRCs could help inform patient response to therapy.

A limitation of the study was that we focused on individual TNM (tumor, node and metastases) factors rather than overall TNM staging. The current study involved two centers with limited numbers of patients that could have been influenced by our local experience in rectal cancer management. Thus, larger, multicenter prospective studies are needed.

4. Materials and Methods {#sec4-cancers-09-00163}
========================

4.1. Patients {#sec4dot1-cancers-09-00163}
-------------

The study was approved by the South Western Sydney Local Health District Human Research Ethics Committee (HREC Reference: HREC/14/LPOOL/186; project number 14/103). Specimens were collected from 266 patients who underwent surgery and radiotherapy for rectal cancer from 2000--2011. Patients were treated with either a 25 Gy dose administered in five treatment fractions, or a 50.4 Gy dose administered in 28 fractions; both treatment groups received 5-fluorouracil-based chemotherapy. Surgery consisted of total mesorectal excision, as well as anterior or abdominoperineal resection. Follow-up included clinic visits, blood tests, colonoscopy, and imaging based on the recommendation of the treating specialist.

4.2. Response and Outcomes of Interest {#sec4dot2-cancers-09-00163}
--------------------------------------

Short-term response to radiotherapy was measured by TRG (tumor regression grade) according to the 7th edition of the American Joint Committee on Cancer manual \[[@B32-cancers-09-00163]\], which describes a scale of 0--3: 0 represents complete response without any viable malignant cells; 1 is a moderate response with small groups of malignant cells; 2 is a minimal response with fibrosis outgrowing residual malignancy; and 3 is a poor response with residual malignancy. Patients categorized with a TRG of 0 and 1 were considered responders, while patients categorized with a TRG of 2 and 3 were considered non-responders. Variables included age, sex, pathological TNM stage, tumor grade, vascular invasion, perineural invasion, the level of tumor-infiltrating lymphocytes, and treatment. Outcomes were DFS, OS, and histologic TRG in the resected bowel. Long-term outcomes were assessed using Kaplan--Meier curves for DFS and OS. DFS was defined as the time from diagnosis to first recurrence, and OS was defined as the time from diagnosis to the last follow-up point or death.

4.3. Sample Preparation and Tissue Microarrays {#sec4dot3-cancers-09-00163}
----------------------------------------------

Archival formalin-fixed, paraffin-embedded tissue blocks from pre- and postoperative rectal cancer tumors were retrieved for each patient, and two cores (1 mm in diameter) were obtained from each of five different sampling sites: tumor center (TC); tumor periphery at invasive edge (TP); normal mucosa close/adjacent to the tumor; normal mucosa well away from the tumor; and the involved lymph nodes. The corresponding hematoxylin and eosin sections were reviewed to localize the most representative areas of tumor and normal colorectal mucosa in tissue samples. These samples were then transferred into pre-drilled wells in tissue microarray blocks using the Beecher Manual Tissue Microarrayer (Beecher Instruments Inc., Sun Prairie, WI, USA), which were mounted on slides for immunohistochemical analysis.

4.4. Immunohistochemistry {#sec4dot4-cancers-09-00163}
-------------------------

Slide sections taken from the tissue microarrays were deparaffinized in xylene and rehydrated in a graded ethanol series. RAD50 antigen retrieval was performed with the Envision^TM^ FLEX Target Retrieval Solution, pH 9.0, in a 98 °C water bath for 45 min. This was followed by incubation with Envision^TM^ FLEX Peroxidase-Blocking Reagent (Dako, Glostrup, Denmark) for 5 min at room temperature to block endogenous peroxidases. Slides were then incubated with a monoclonal anti-RAD50 primary antibody \[13B3/2C6\] (1:400 dilution, Abcam \#ab89; Cambridge, UK) for 60 min at room temperature. Following antigen retrieval, primary antibodies against MSH6 (1:100), and PMS2 (1:100) (all from Dako, Glostrup, Denmark) were applied for 15 min on board the Dako Autostainer (Dako, Glostrup, Denmark) in 1 mM EDTA (Ethylenediaminetetraacetic acid) buffer, pH 8.0. After washing with Tris-buffered saline with Tween-20, slides were incubated for 15 min with DAKO mouse linker, rinsed, and incubated for 30 min with an anti-mouse secondary antibody. A mixture of Envision^TM^ FLEX DAB + Chromogen DM827 and Envision^TM^ FLEX Substrate Buffer DM823 (Dako, Glostrup, Denmark) was used as a substrate for development. Finally, slides were counterstained with hematoxylin, washed with cold water, and then dipped 10 times in Scott's Bluing solution (Thermo Fisher Scientific, North Ryde, NSW, Australia). Slides were rinsed immediately with cold water before dehydration and mounting.

Two independent pathologists recorded the intensity and percentage of positive immunohistochemical staining in each sample. RAD50 expression was scored as the product of the staining percentage and intensity as previously described \[[@B20-cancers-09-00163]\]. Intensity was graded as follows: 0, negative; 1, weak; 2, moderate; or 3, strong. The percentage of positive cells was graded as follows: 0 (\<5%), 1 (5--25%), 2 (26--50%), 3 (51--75%), or 4 (\>75%). These two measures were multiplied to obtain weighted scores ranging from 0 to 12. All tumor samples were categorized into either a low expression group (score range: 0--\<6) or a high expression group (score range: 6--12).

4.5. Statistical Analysis {#sec4dot5-cancers-09-00163}
-------------------------

Statistical analysis was performed with SPSS for Windows 22.0 (IBM Corporation, Armonk, NY, USA). Survival analysis was conducted for the entire cohort. In addition, further subgroup analysis was conducted for early tumor stage and low-grade tumors as covariates. Univariate and multivariate analyses were performed using Kaplan--Meier curves and Cox's proportional hazards survival modeling for RAD50 protein expression from the cancer core and periphery. Covariates were sex, age, TNM stage, tumor grade, vascular invasion, perineural invasion, chemotherapy and radiotherapy, TRG, MSH6, and PMS2. Univariate analysis was performed using the Mann--Whitney U test. *p* \< 0.05 was considered statistically significant.

5. Conclusions {#sec5-cancers-09-00163}
==============

The status of RAD50 expression may have treatment implications for rectal cancer, particularly for predicting long-term survival of patients with perineural invasion and for potential use in early stage and low-grade rectal cancer assessment. Further investigation of RAD50 in larger populations and the identification of new biomarkers are likely to provide new and effective prognostic tools for rectal cancer management.
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![Association between postoperative RAD50 (DNA repair protein RAD50 homolog) expression in the TC (tumor core) and TP (tumor periphery) and survival. (**A**--**D**) Kaplan--Meier survival analysis illustrating DFS (disease free survival) (**A**,**C**) and OS (overall survival) (**B**,**D**) of patients with RAD50 expression in the TC (**A**,**B**) and TP (**C**,**D**). Blue lines represent patients with low RAD50 expression and green lines represent patients with high RAD50 expression.](cancers-09-00163-g001){#cancers-09-00163-f001}

###### 

Correlation between RAD50 expression and perineural invasion (PNI) and survival in early stage rectal cancers. (**A**,**B**) Representative immunohistochemical staining of RAD50 in rectal cancer samples (high versus low expression), images were taken at 10× magnification; (**C**,**D**) Kaplan--Meier survival analysis of DFS in low RAD50 expression (**C**) and high RAD50 expression (**D**) groups with (green line) or without (blue line) perineural invasion; (**E**,**F**) Kaplan--Meier survival analysis illustrating the relationship of RAD50 expression with DFS (**E**) and OS (**F**) in low-grade (G1--2) with early tumor stage (T1--2) subgroup. The analyses were divided into four subgroups including the low-grade with early stage tumors (G1--2, T1--2, *n* = 64), high-grade with early stage tumors (G3, T1--2, *n* = 4), low-grade with late stage tumors (G1--2, T3--4, *n* = 113), and high-grade with late stage tumors (G3, T3--4, *n* = 8).
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cancers-09-00163-t001_Table 1

###### 

Patient characteristics.

  Variables             All Patients (%)
  --------------------- ------------------
  Total, *n*            266
  Age median            72
  Sex                   
     Male               176/266 (66.2)
     Female             90/266 (33.8)
  Tumor stage           
     T1--2              88/266 (33.1)
     T3--4              172/266 (66.9)
  Node stage            
     N0                 140/259 (54.1)
     N1--2              119/259 (55.9)
  Metastasis stage      
     M0                 223/240 (92.9)
     M1                 17/240 (7.1)
  Histological Grade    
     1--2               246/266 (92.5)
     3                  20/266 (7.5)
  Vascular invasion     
     Absent             201/263 (76.4)
     Present            62/263 (23.6)
  Perineural invasion   
     Absent             220/263 (83.7)
     Present            43/263 (16.3)
  Radiotherapy          
     Total              77/246 (31.3)
     Neoadjuvant        55/77 (71.4)
     Adjuvant           22/77 (28.6)

cancers-09-00163-t002_Table 2

###### 

Associations between RAD50 protein expression in the tumor center and tumor periphery and clinicohistopathological data.

  Variables                Subgroups   Tumor Center   Tumor Periphery                        
  ------------------------ ----------- -------------- ----------------- ------ ------ ------ ------
  Sex                      Male        26.3           73.7              0.98   29.6   70.4   0.42
  Female                   26.1        73.9                             34.4   65.6          
  Age                      ≤72         28.8           71.2              0.39   30.6   69.4   0.82
  \>72                     24.1        75.9                             31.9   68.1          
  Tumor stage              T1--2       23.5           76.5              0.65   32.1   67.9   0.68
  T3--4                    26.2        73.8                             29.6   70.4          
  Node stage               Negative    26.5           73.5              0.67   31.1   68.9   0.95
  Positive                 24.1        75.9                             30.8   69.2          
  Metastasis stage         M0          25.5           74.5              0.72   31.5   68.5   0.09
  M1                       29.4        70.6                             11.8   88.2          
  Histological Grade       1--2        26.1           73.9              0.88   31.3   68.7   0.98
  3                        27.8        72.2                             31.6   68.4          
  Vascular invasion        Absent      26.3           73.7              0.74   31.9   68.1   0.50
  Present                  24.2        75.8                             27.4   72.6          
  Perineural invasion      Absent      24.7           75.3              0.40   32.2   67.8   0.28
  Present                  31.1        68.9                             23.8   76.2          
  Adjuvant therapy         No          25.2           74.8              0.83   24.8   75.2   0.04
  Yes                      26.6        73.4                             38.8   61.2          
  Neoadjuvant therapy      No          23.8           76.2              0.14   27.1   72.9   0.16
  Yes                      34.1        65.9                             37.3   62.7          
  Tumor regression grade   0--1        50             50                0.14   50     50     0.22
  2--3                     28.3        71.7                             32.8   67.2          
  MSH6                     Negative    50.0           50.00             0.43   0      100    0.35
  Positive                 25.5        74.5                             30.8   69.2          
  PMS2                     Negative    55.6           44.4              0.04   44.4   55.6   0.36
  Positive                 25.5        74.5                             30.1   69.9          

RAD50: DNA repair protein RAD50 homolog; MSH6: MutS protein homolog 6; PMS2: PMS1 homolog 2.

cancers-09-00163-t003_Table 3

###### 

Cox regression analyses of postoperative RAD50 with disease-free survival.

  Variables               Univariate   Multivariate                                    
  ----------------------- ------------ ---------------- ------- ------- -------------- -------
  RAD50                                                                                
     Low                  0.552        0.339--0.899     0.017   0.567   0.345--0.931   0.025
     High                                                                              
  Age                                                                                  
     ≤72                  1.279        0.785--2.086     0.323                          
     \>72                                                                              
  Sex                                                                                  
     Male                 1.074        0.657--1.754     0.776                          
     Female                                                                            
  Tumor stage                                                                          
     T1--2                1.643        0.983--2.747     0.058                          
     T3--4                                                                             
  Node stage                                                                           
     Negative             1.198        0.709--1.827     0.593                          
     Positive                                                                          
  Histological Grade                                                                   
     1--2                 1.646        0.712--3.804     0.244                          
     3                                                                                 
  Vascular invasion                                                                    
     Absent               1.888        0.650--0.2.171   0.575                          
     Present                                                                           
  Perineural invasion                                                                  
     Absent               2.534        0.373--1.134     0.001   2.364   1.343--4.162   0.003
     Present                                                                           
  Adjuvant therapy                                                                     
     No                   0.65         0.373--1.134     0.129                          
     Yes                                                                               
  Neoadjuvant therapy                                                                  
     No                   1.147        0.672--0.957     0.616                          
     Yes                                                                               
  T1--2, G1--2, † RAD50                                         0.218   0.084--0.570   0.002
  T3--4, G3, † RAD50                                            0.401   0.065--2.471   0.324

HR, hazard ratio; CI, confidence interval; TC, tumor center, † denotes interaction.

[^1]: These authors contributed equally to this work.
